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Difference in harmonic content was 0.4 mm Hg for the first
eight harmonics, which contained 99.9% of cumulative power.
Thus, the Millar tonometer provides a robust method for high-
fidelity recording of the important features of the radial waveform.
The generalized transfer function used in sphygmoCor is
virtually identical to that described by Lasance et al. (4), as well as
by Karamanoglu et al. (5), and its utility was described by Chen et
al. (6). Its validity has also been confirmed in a realistic model of
the human upper limb (7). When this generalized transfer function
was prospectively validated against invasively recorded aortic pres-
sures in a large group of patients, the mean offset for systolic,
diastolic, mean, and pulse pressures was 1 mm Hg (SD 4.5)
(8). Differences were slightly greater (mean 4 mm Hg, SD 7)
for augmented and end-systolic pressures (9) but still within the
Association for the Advancement of Medical Instrumentation
(AAMI) SP10 criteria for “substantial equivalence.” Therefore, we
believe that the validity of the transfer function itself is proven, and
we understand that the Food and Drug Administration (FDA) has
accepted use of the sphygmoCor system when combined with
accurate intra-arterial manometer systems, and with the noninva-
sive Millar tonometer. Nevertheless, we have retrospectively com-
pared augmentation index in the radial artery between the two
groups in our original study (1). Radial augmentation was en-
hanced in the hypercholesterolemic subjects (66 vs. 78%; p 
0.001), suggesting that the observed differences in central augmen-
tation were not due to the transfer function per se. Rather, the
transfer function permits accurate, noninvasive determination of
central pressures and thus left ventricular load.
Finally, Dr. Hope and colleagues question cuff calibration of
peripheral waveforms. Although we agree that invasive radial
waveforms were used in the most recent validation study (8), such
an approach tests the validity of the transfer function itself. We
also accept that not all automated sphygmomanometers are accu-
rate. However, we used a device that meets both the British
Hypertension Society and AAMI standards (Omron, 705CP),
thus minimizing any potential source of error (10). The investi-
gators should remember that such scaling issues also apply to other
techniques—for example, when carotid waveforms are scaled to
pressures recorded by sphygmomanometry in the arm (2,11).
Moreover, such investigators have not always used validated
devices (12). We trust we have put to rest the concerns voiced by
Dr. Hope and colleagues about the transfer function, and we await
with interest the results of the large-scale outcome studies using
sphygmoCor currently in progress, as we are sure they do too.
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Enoxaparin After
High-Risk Coronary Stenting
We read with interest the report by Batchelor et al. (1), published
in the November 15, 2001, issue of the Journal. They conclude
that, given the relative safety of enoxaparin and the potential to
reduce the risk of subsequent infarction, a 14-day course of
enoxaparin may be considered for carefully selected patients. We
would like to comment on some aspects of their study.
The investigators’ conclusion is based on the finding of a
reduction of myocardial infarction at 30 days. This variable was
neither the primary end point nor a predefined secondary end
point in their study. The fact that the study was stopped prema-
turely owing to a low rate of events does not, in our opinion, allow
one to conclude a therapeutic recommendation. Of course, it is
possible that the end point was not achieved because of a beta
error, as pointed out by the researchers, but we do not know what
the outcome would be in a study including at least 3,590 patients,
which was the recalculated sample size. Contrarily, Batchelor et al.
(1) affirm that rates of major bleeding (3.3% for enoxaparin, 1.6%
for placebo, p  0.08) were comparable. In reality, the rate of this
event with enoxaparin was two times higher than with placebo,
and the p value was next to the conventionally accepted signifi-
cance level. In this case, the lack of statistical significance could
also be due to a beta error, but this is omitted by the investigators.
Some aspects of the discussion deserve comment. It is men-
tioned that enoxaparin’s clinical superiority over unfractionated
heparin (UFH) has been shown in patients with acute coronary
syndromes (2–4) and that extended low-molecular-weight hepa-
rins (LMWHs) also reduce the short-term risk of thrombotic
events, although benefits are not sustained at six months (5). In the
same manner that it is mentioned that enoxaparin was superior to
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UFH, it should be specified that the benefit derived from extended
LMWH use was obtained with dalteparin in the FRISC II study
(5). Neither in the TIMI-11B (4) nor in the FRAXIS (6) studies,
a benefit associated with the extended treatment of enoxaparin or
fraxiparin, respectively, was not evidenced. As has been pointed
out, LMWHs should not be regarded as interchangeable, but
rather as distinct drugs with specific structural and functional
profiles that require individual investigation (7). Thus, results
obtained with one LMWH cannot be extrapolated to the other
products.
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